Todd Brady Biography and Net Worth

Chief Executive Officer, President & Director of Aldeyra Therapeutics

Dr. Brady has served as the President and Chief Executive Officer of Aldeyra since 2012 and as a member of our board of directors since 2005. Prior to Aldeyra, Dr. Brady served as Entrepreneur in Residence at Domain Associates, LLC, a healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady serves on the board of directors of Evoke Pharma, Inc. a publicly traded specialty pharmaceutical company. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, an M.D. from Duke University Medical School, and an A.B. from Dartmouth College.

What is Todd C. Brady's net worth?: The estimated net worth of Todd C. Brady is at least $3.96 million as of June 3rd, 2026. Dr. Brady owns 1,721,298 shares of Aldeyra Therapeutics stock worth more than $3,958,985 as of July 10th. This net worth evaluation does not reflect any other assets that Dr. Brady may own. Learn More about Todd C. Brady's net worth.
How do I contact Todd C. Brady?: The corporate mailing address for Dr. Brady and other Aldeyra Therapeutics executives is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. Aldeyra Therapeutics can also be reached via phone at 781-761-4904 and via email at [email protected]. Learn More on Todd C. Brady's contact information.
Has Todd C. Brady been buying or selling shares of Aldeyra Therapeutics?: Todd C. Brady has not been actively trading shares of Aldeyra Therapeutics within the last three months. Most recently, on Wednesday, June 3rd, Todd C. Brady bought 250,000 shares of Aldeyra Therapeutics stock. The stock was acquired at an average cost of $1.67 per share, with a total value of $417,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,721,298 shares of the company's stock, valued at $2,874,567.66. Learn More on Todd C. Brady's trading history.
Are insiders buying or selling shares of Aldeyra Therapeutics?: In the last year, Aldeyra Therapeutics insiders bought shares 3 times. They purchased a total of 325,000 shares worth more than $522,600.00. In the last year, insiders at the biotechnology company sold shares 1 times. They sold a total of 22,073 shares worth more than $113,675.95. The most recent insider tranaction occured on June, 3rd when CEO Todd C Brady bought 250,000 shares worth more than $417,500.00. Insiders at Aldeyra Therapeutics own 11.8% of the company. Learn More about insider trades at Aldeyra Therapeutics.
Information on this page was last updated on 6/3/2026.

Todd C. Brady Insider Trading History at Aldeyra Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/3/2026	Buy	250,000	$1.67	$417,500.00	1,721,298
3/11/2024	Sell	97,914	$3.27	$320,178.78	1,556,622
6/23/2022	Buy	17,700	$3.36	$59,472.00	1,216,535
12/16/2019	Buy	20,000	$5.83	$116,600.00	652,216
9/30/2019	Buy	8,710	$5.68	$49,472.80	632,216
9/23/2019	Buy	8,680	$5.81	$50,430.80	623,506
9/18/2019	Buy	14,288	$5.91	$84,442.08	614,826
9/16/2019	Buy	3,000	$6.03	$18,090.00	588,991
9/9/2019	Buy	10,000	$4.89	$48,900.00	50,000
2/17/2017	Buy	22,223	$4.50	$100,003.50	64,408

Todd C. Brady Buying and Selling Activity at Aldeyra Therapeutics

Aldeyra Therapeutics Company Overview

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Today's Range

Now: $2.30

$2.06

$2.31

50 Day Range

MA: $1.82

$1.50

$2.43

2 Week Range

Now: $2.30

$1.07

$6.18

Volume

2,081,471 shs

Average Volume

1,876,928 shs

Market Capitalization

$138.74 million

P/E Ratio

N/A

Dividend Yield